Skip to main content

Nussdorf Glenn H's Form 4 filing

Organogenesis Holdings Inc. (ORGO) · filed Jan 11, 2024

Accession no.
0001062993-24-000798
Filed
Jan 11, 2024, 4:44 PM ET
Trade date
Jan 9-10, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market sales total $940.9K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Nussdorf Glenn HCIK 0001244191Director, 10% Owner
Ades Alan A.CIK 0001757286Director, 10% Owner
Erani AlbertCIK 000107408410% Owner
GN 2016 Family Trust u/a/d August 12, 2016CIK 000175745310% Owner
Dennis Erani 2012 Issue Trust dated 12/20/12CIK 000175745510% Owner
Alan Ades 2014 GRATCIK 000175756710% Owner
Organo Investors LLCCIK 000175757310% Owner
Organo PFG LLCCIK 000175758010% Owner
Albert Erani Family Trust dated 12/29/2012CIK 000176066310% Owner
Wisdom StarrCIK 000176069410% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 9, 2024Class A Common StockSSaleDisposed−197,921$4.37F1−$863,984.5459,025,106Direct
Jan 10, 2024Class A Common StockSSaleDisposed−17,972$4.28F3−$76,875.2359,007,134Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $4.30 to $4.45, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $4.20 to $4.34, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

Referenced by the price of 1 transaction in Table I.

Remarks

Alan A. Ades, Albert Erani, Glenn H. Nussdorf, Dennis Erani, Starr Wisdom and certain of their respective affiliates, including Organo PFG LLC, Organo Investors LLC, Dennis Erani 2012 Issue Trust, Alan Ades as Trustee of the Alan Ades 2014 GRAT, Albert Erani Family Trust dated 12/29/2012, GN 2016 Family Trust u/a/d August 12, 2016, GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 and RED Holdings, LLC, referred to collectively as the "Group", are parties to a Controlling Stockholders' Agreement dated December 10, 2018 with Organogenesis Holdings Inc. (the "Stockholders' Agreement"). The Stockholders' Agreement, among other things, provides for nomination rights of the Group with respect to four directors of the Issuer. As a result of the Stockholders' Agreement, the reporting persons may be deemed to be members of a group holding over 10% of the outstanding shares of common stock of the issuer for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. This is Form 4 No. 1 of 2 filed for the Group.

Read the full filing on SEC EDGAR (opens in a new tab)